On March 15, 2023 lino Biotech, a leading biosensor company and the world’s only provider of Focal Molography, reported it has been acquired by Miltenyi Biotec, a global biotech company based in Germany, on February 22, 2023 (Press release, Miltenyi Biotec, MAR 15, 2023, View Source [SID1234628839]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Since its founding in 2020, lino Biotech has made significant advances in developing new biosensors to facilitate quality control in bioprocessing, measuring viral load in cell & gene therapy manufacturing, and testing for off-target responses in living cells to support drug discovery.

Headquartered in Bergisch Gladbach, Miltenyi Biotech has been a global provider of products and services for biomedical research and cellular therapy for more than 30 years.

Under the terms of the transaction, Miltenyi Biotech will acquire 100% of the shares from the investors including Roche Venture Fund and High-Tech Gründerfonds. The specific terms of the transaction were not disclosed.

"lino´s innovative biosensor platform and Miltenyi’s cell and gene therapy approaches offer exciting synergies to lower the cost and establish a new standard for potency assays," said Dr. Mirko Stange, CEO of lino Biotech.

lino’s headquarters in Zurich will be further expanded for research, chip, and application development.